ixazomib
MLN9708 (ixazomib citrate), MLN2238 (active boronic acid), ixazomib citrate
Ixazomib is the first orally bioavailable proteasome inhibitor, given as a boronic ester that hydrolyses to the active boronic acid on contact with plasma. It offers convenience and a much longer plasma half-life than injectable proteasome inhibitors, and it clearly prolongs progression-free survival, but the final analysis of its pivotal trial found no overall survival benefit, and its European authorisation remains conditional a decade on.
Mechanism
Ixazomib, like bortezomib, is a peptide boronic acid that reversibly inhibits the chymotrypsin-like (β5) proteolytic site of the 20S proteasome. The boron atom coordinates the catalytic Thr1 hydroxyl, producing a tetrahedral adduct that blocks substrate turnover. Its molecular design differs from bortezomib in two ways that matter. First, the dissociation kinetics are much faster: the reported proteasome-binding half-life is around 18 minutes for ixazomib versus of the order of 110 minutes for bortezomib. Counterintuitively this improves tissue penetration. A drug that lets go quickly redistributes out of the first tissues it encounters (blood, liver, spleen) and reaches deeper compartments such as the bone marrow more evenly. Second, the smaller, more lipophilic dichlorobenzamide-glycine-leucine framework confers oral bioavailability of roughly 58%.
The product administered is ixazomib citrate, a stable boronic ester in which citrate caps the boron. On dissolution in aqueous media or on contact with plasma this hydrolyses within moments to release the active boronic acid, so the citrate is a formulation device rather than a metabolic prodrug in the classical sense. Downstream consequences are those of proteasome inhibition generally: accumulation of polyubiquitinated substrates, unfolded protein response activation with CHOP and NOXA induction, IκBα stabilisation with loss of NF-κB signalling, and apoptosis preferentially in immunoglobulin-secreting plasma cells. Ixazomib is metabolised by multiple CYP isoforms with no single dominant route at clinical concentrations, though strong CYP3A4 inducers meaningfully reduce exposure.
What the research shows
TOURMALINE-MM1 randomised 722 patients with relapsed or refractory myeloma to ixazomib or placebo added to lenalidomide and dexamethasone. Median progression-free survival was 20.6 versus 14.7 months (HR 0.74), a statistically robust result, with the benefit apparent across subgroups including patients with high-risk cytogenetics such as del(17p), a point often emphasised, though the subgroup numbers were small and not powered for independent inference. TOURMALINE-MM3 then tested single-agent ixazomib as maintenance after autologous stem-cell transplantation in 656 patients, finding median progression-free survival of 26.5 versus 21.3 months with placebo (HR 0.72), with a favourable tolerability profile including low rates of second primary malignancy.
The honest caveat is important. The final overall survival analysis of TOURMALINE-MM1, published in 2021 after a median follow-up of around 85 months, found median overall survival of 53.6 months with ixazomib versus 51.6 months with placebo, a difference of two months that was not statistically significant (HR 0.94). A progression-free survival gain of six months that does not translate into longer life is a legitimate reason for regulators and health technology assessment bodies to be cautious, and it is why the European authorisation was granted conditionally and has never been converted to a standard one. Ixazomib's real-world position is therefore as a convenience option (an all-oral triplet, valuable for patients for whom frequent injections are impractical, for those with existing neuropathy, and during periods when clinic attendance is difficult) rather than as the most potent proteasome inhibitor available.
Evidence assessment
Mixed evidence
Downgraded from 'strong' by this audit. The trial evidence itself is methodologically good: two randomised, double-blind, placebo-controlled phase 3 trials (TOURMALINE-MM1 and TOURMALINE-MM3) that both met their primary progression-free survival endpoints, all verified against PubMed. But the pre-specified final overall survival analysis of TOURMALINE-MM1, at roughly seven years of follow-up, was null (53.6 versus 51.6 months, HR 0.94), the absolute gains are modest, and the European conditional marketing authorisation granted in November 2016 has still not been converted to a standard one as of August 2026. Strong evidence for a progression-free survival effect plus absent evidence for a survival effect is a mixed picture, and calling it 'strong' overall would flatter it.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma Preclinical only
Median progression-free survival 20.6 versus 14.7 months (HR 0.74) when ixazomib was added to lenalidomide and dexamethasone. Basis for approval as the first oral proteasome inhibitor.
Final overall survival analysis of the TOURMALINE-MM1 phase III trial of ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma Preclinical only
Median overall survival 53.6 versus 51.6 months (HR 0.94), no statistically significant survival benefit despite the earlier progression-free survival gain. A key negative result for interpreting the drug's value.
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial Preclinical only
Median progression-free survival 26.5 versus 21.3 months (HR 0.72). Low discontinuation for adverse events and no excess of second primary malignancies, but a modest absolute gain and no demonstrated survival benefit.
Safety
The commonest problems are gastrointestinal: diarrhoea, constipation, nausea and vomiting, all usually manageable and often intermittent around dosing days. Thrombocytopenia is common and cyclical, recovering between cycles. Peripheral neuropathy occurs but is generally milder than with intravenous bortezomib, with grade 3 events uncommon. Peripheral oedema, rash, back pain and upper respiratory infection are frequent. Less common but serious events in the labelling include thrombotic microangiopathy, posterior reversible encephalopathy syndrome, hepatotoxicity, transverse myelitis and severe cutaneous reactions including Stevens-Johnson syndrome. Herpes zoster prophylaxis is generally advised. Strong CYP3A4 inducers such as rifampicin, carbamazepine and St John's wort substantially lower exposure and should be avoided. Ixazomib is embryo-foetal toxic and contraception is required.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | The European Commission granted a conditional marketing authorisation on 21 November 2016 for use with lenalidomide and dexamethasone after at least one prior therapy. Verified against the EMA product record in August 2026: the authorisation remains conditional, subject to annual renewal and ongoing data obligations, and has never been converted to a standard authorisation. Licensed in Great Britain by the MHRA. NHS access in England is restricted and narrower than the licensed indication; current NICE guidance should be checked. |
| United States | FDA approved November 2015 in combination with lenalidomide and dexamethasone for adults with multiple myeloma who have received at least one prior therapy, the first oral proteasome inhibitor approved anywhere. Oral capsule, prescription-only. |
| WADA (sport) | Not on the WADA Prohibited List. It has no anabolic, hormonal or masking properties and is outside all prohibited categories. |
Questions
Ixazomib citrate is a boronic ester. The citrate caps the reactive boron atom, making a stable, crystalline solid suitable for a capsule. On contact with aqueous fluid or plasma it hydrolyses almost instantly to release the active boronic acid. It is a formulation trick rather than a metabolic prodrug that needs enzymatic activation.
On the current evidence, no. The final overall survival analysis of TOURMALINE-MM1, at around seven years of follow-up, found 53.6 versus 51.6 months, a two-month difference that was not statistically significant. It does delay progression by about six months, and that has value, but a survival benefit has not been shown.
A conditional marketing authorisation is granted when a medicine addresses an unmet need but the evidence package is incomplete, and it is renewed annually while the company supplies further data. Ixazomib was authorised conditionally on 21 November 2016 and, as of August 2026, remains so, reflecting continuing questions about the size and durability of the benefit.
It is taken by mouth once weekly rather than injected, causes considerably less peripheral neuropathy, and has a very long plasma half-life of around 9.5 days. Head-to-head randomised comparison against bortezomib has not been done, so claims of superiority in either direction are not supported by direct evidence.
Because a molecule that binds and holds on tightly gets trapped in the first well-perfused tissues it encounters. Ixazomib's short binding half-life of about 18 minutes lets it dissociate and redistribute, so it reaches compartments such as bone marrow more evenly. It is a genuine example of a faster off-rate producing better distribution.